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Abstract 
Introduction 
The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT1) 
2013 guideline provides guidance to improve the quality of protocols. The aim of this 
study was to determine the completeness of randomised controlled trial protocols 
evaluating the efficacy or effectiveness of HIV prevention, treatment and care 
strategies using the SPIRIT 2013 checklist, and to identify factors associated with 
completeness of trial protocols.  
Methods 
We searched MEDLINE, EMBASE, LILACS, Africa-wide information (EBSCOhost), 
Web of Science, Clinicaltrials.gov and CENTRAL (Wiley Cochrane Library) for 
randomized controlled trial protocols in May and June 2018. We included protocols 
for interventions in the HIV prevention, treatment and care fields published between 
2008 and 2018. Two individuals independently screened the titles and abstracts. The 
adapted SPIRIT checklist was pilot tested independently in duplicate on the first 4 
(5%) protocols. The rest of the data was collected by a single individual and verified 
by second reviewer. Disagreements were resolved by consensus. We summarized 
categorical data using count (percent) and continuous variables using mean 
(standard deviation). Generalised estimation equations assuming a Poisson 
distribution were used to assess association of protocol factors with number of 
checklist items reported. 
Results 
Seventy-nine protocols met the eligibility criteria and were included in the analysis. A 
mean of 32 (SD= 5) of the possible 51 SPIRIT checklist items were reported in the 
protocols. Detailed methodological aspects relating to intervention allocation, 
blinding, data management, study monitoring and dissemination policy information 
were often missing in the protocols. Intervention category, period of publication 
(before or after SPIRIT 2013 publication) and study setting were not significantly 
associated with protocol completeness.  
Conclusion 
There is need for improvement in the reporting of recommended SPIRIT 2013 
checklist items in HIV intervention protocols. We recommend active implementation 
1 Abbreviation: SPIRIT-  Standard Protocol Items: Recommendations for Interventional Trials 
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strategies of the SPIRIT guideline from publishing journals and HIV trialists to ensure 
more improvement in protocol quality.  
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1. Introduction 
1.1 Background 
Protocol publication is  good practice as it increases transparency in research. The 
practice has evolved over the years from voluntary publication of links to full 
protocols in the results publications, to recommendations of prospective publication 
of protocols as pre-requisites for results publication by journals. The subsequent 
development of the EQUATOR network, which has guidelines and resources for 
writing and publishing protocols and clinical research is a great resource in this area 
[1, 2]. However, completeness and availability of protocols still remains poor [3, 4].   
 
Published protocols should provide sufﬁcient detail to enable understanding of the 
background, rationale, objectives, study population, interventions, methods, 
statistical analyses, ethical considerations, dissemination plans and administration of 
the trial, so as to enable replication of key aspects of trial methods and conduct [5]. 
Beyond trial conduct, the clarity of the protocol should facilitate proper appraisal of 
the scientific rigor by journal editors during peer review and systematic reviewers [6].    
 
Empirical evidence comparing randomized controlled trial results publications and 
their corresponding protocols revealed unclear descriptions of allocation 
concealment in 83% of protocols reviewed, which potentially introduces selection 
bias during trial conduct [7]. Sample size and statistical plans were also found to be 
discrepant between protocol and final study publications in 82% of studies, which is 
associated with biased trial results and conclusions [3]. Biased results and 
conclusions may result in ill-informed policies to the detriment of human health. Poor 
reporting of methodological details may also necessitate protocol amendments which 
increases the costs of the research process and delay study conduct. 
 
Empirical evidence of poor reporting in published protocols underscored the need for 
guidance to help improve the completeness and transparency of trial protocols. In 
2013, a multiple stakeholder and evidence informed guidance document, the 
Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 
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statement, was published [8]. It defined the minimum recommended standard items 
to be reported in interventional trial protocols [8].  
 
A study evaluating reporting quality of protocols in the National Institute for  Health 
Research Health Technology Assessment (NIHR-HTA2) database revealed that on 
average 63% of SPIRIT recommendations were reported [9]. However, this study 
was done seven months after the publication of the SPIRIT guideline, hence the 
impact of the guideline may not have been realised at that time.  
 
HIV/AIDS is a public health priority and the field is fast evolving. Various 
interventions and strategies targeting prevention efforts, the care continuum from 
diagnosis, linkage to care, retention in care, with the desired outcome of viral 
suppression are under evaluation [10]. Given the pandemic nature of the disease, 
consequences of recommending inappropriate interventions caused by flawed study 
methodologies are significant at the individual and population level. It is therefore 
critical to investigate the status of protocol reporting in this field. There is no 
published study to our knowledge on the completeness of randomised controlled trial 
protocols in the HIV prevention, treatment and care field. 
 
This manuscript was prepared following the PRISMA checklist, Appendix A. The 
protocol for the study is attached as Appendix B. 
 
1.2 Study aim, objectives and hypotheses 
Study aim  
To assess the completeness of reporting of randomised controlled trial protocols 
evaluating the efficacy or effectiveness of HIV prevention, treatment and care 
interventions using the SPIRIT 2013 checklist.  
Study objectives 
To determine how many items of SPIRIT guideline are documented in the trial 
protocols.  
To determine study characteristics associated with completeness of reporting of trial 
protocols.  
                                               
2 Abbreviation: NIHR-HTA -National Institute for  Health Research Health Technology Assessment 
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Study hypotheses 
Hypothesis 1: SPIRIT endorsement of protocol publishing journal is associated with 
higher number of SPIRIT checklist items reported compared to non-endorsement by 
journals. 
Hypothesis 2: SPIRIT checklist items reported in the different intervention categories 
HIV prevention alone; HIV treatment and prevention combined; HIV treatment and 
care are different.  
Hypothesis 3: Multiple site studies are associated with higher number of SPIRIT 
checklist items reported compared to single site studies.  
Hypothesis 4: Protocols published in post-SPIRIT 2013 publication are associated 
with higher number of SPIRIT checklist items reported compared to those published  
pre-SPIRIT 2013 publication.  
2. Methods and materials 
2.1 Study design 
The study is a systematic survey of HIV intervention protocols published between 
2008 and 2018. 
 
2.2  Eligibility criteria 
Eligible articles were study protocols for randomised controlled trials (cluster, 
parallel, factorial or pragmatic design). Protocols investigating efficacy or 
effectiveness of pharmacological or non-pharmacological interventions, for HIV care, 
treatment and  prevention. Protocols investigating efficacy or effectiveness of HIV 
related services or procedures for example counselling and testing services,  linkage 
to care, adherence and retention. We included protocols published between 2008 
and 2018 because we wanted to determine differences in protocol completeness 5 
years prior to and 5 years post publication of the SPIRIT 2013 guidelines. 
Ineligible articles were pilot or feasibility studies to determine feasibility of conducting 
a larger trial. 
2.3 Study search 
Between 29 May and 01 June 2018, a researcher not involved in the survey 
conducted a database search for published randomised controlled trial protocols 
investigating HIV care, treatment and prevention interventions. We searched 
MEDLINE, EMBASE, LILACS, Africa-wide information (EBSCOhost), Web of 
Stellenbosch University  https://scholar.sun.ac.za
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Science, Clinicaltrials.gov and CENTRAL (Wiley Cochrane Library) using medical 
subject headings (MESH) terms and search terms to identify the protocols. There 
was no language limitation in the search (see search strategy in Appendix C).  
2.4 Study selection 
Two reviewers (SS and MD) screened the titles and abstracts independently, using 
Covidence systematic reviews software (Veritas Health Innovation, Melbourne, 
Australia). Disagreements were resolved through discussion until consensus was 
reached. Following title and abstract screening, full texts of potentially eligible 
protocols were obtained and independently screened. 
2.5 Data extraction  
The SPIRIT checklist was adapted for this study. We also collected the following 
general information: year of publication, journal name, journal endorsement of 
SPIRIT statement (checked from SPIRIT website), whether it was a single or multiple 
site trial,  study funding source and a brief description of the study intervention and 
intended outcomes to enable classification of the trials into different intervention 
categories. The adapted study checklist is attached as Appendix D. The first four 
(5%) protocols were reviewed and data extraction done independently by two 
individuals (SS and MD) in a pilot test of the checklist. Ratings were compared for all 
the items and conflicts resolved by discussion. The rest of the protocols were single 
extracted by SS and reviewed by MD. The reviewers were not blinded to the 
publishing journals.  
 
Assessment of trial protocol completeness was done using the 33 items of the 
SPIRIT checklist which are recommended for inclusion in a trial protocol [5]. The 
individual recommendations of items with subcategories were retained to give a total 
of 51 items for which inclusion in the protocol was judged. Checklist items reported in 
the protocol were recorded as “yes” and unreported items as “no”. Items deemed as 
not applicable were checked as such. The number 1 was assigned to all “yes” 
responses and 0 to “no” responses. For an item with multiple components 
recommended, failure to satisfy all components would result in the item being 
assigned the number 2 and notes taken on the missing components. We 
summarized the information that was commonly missing on those items. However 
items rated 1 and 2 were combined during analysis. The data extracted for each 
Stellenbosch University  https://scholar.sun.ac.za
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protocol is provided as supplementary file 1 in excel format together with the 
codebook to assist with review of the spreadsheet. 
2.6 Data analysis 
We summarized categorical data using count (percent).  We summarized the 
number of items in the SPIRIT guidelines that were reported in the study protocols 
using mean (standard deviation). Overall completeness of the protocol was 
calculated as the total number of the yes responses out of the total number of 
applicable items. We used generalized estimation equations (GEE3) assuming a 
Poisson distribution with an exchangeable correlation structure to determine factors 
associated with the number of SPIRIT guideline items reported. The GEE model 
accounted for within-journal clustering of the published protocols and we also 
adjusted for the number of items applicable for the specific protocol. The factors 
explored were: SPIRIT endorsement of protocol publishing journal; intervention 
category (HIV prevention alone; HIV treatment and prevention combined; HIV 
treatment and care); study setting (multiple or single site); and publication period 
(pre-SPIRIT 2008 to 2013 and post-SPIRIT 2014 to 2018). We hypothesised that 
these covariates would be associated with the number of checklist items reported. 
We required 37 protocols for the primary analysis (based on an estimated mean 
number of checklist items reported) , with an upward adjustment of 10 protocols for 
each factor we included in the GEE model to give a total of 87 protocols. Data 
analyses was performed using STATA 15 (Stata Corp., College Station, Texas, 
USA). 
3. Results 
3.1 Results of the search  
The database search outputs yielded a total of 4871 references. After removing 
duplicates (n = 632) and non-eligible articles (n = 4119) articles after title and 
abstract screening, 120 protocols had full text screening with 79 protocols meeting 
the eligibility criteria (see Figure 1). A list of excluded protocols and reasons for 
exclusion is presented in Appendix E. 
 
                                               
3 Abbreviation: GEE- Generalised estimation equations 
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3.2 Characteristics of included protocols 
Characteristics of included protocols are summarized in  Table 1. Characteristics of 
each protocol included and their references are presented in Appendix F. About 
three quarters (75%) of included studies were published after SPIRIT 2013 
publication. Only 2 (3%) studies were industry funded. Over a third (35%) of the 
protocols were published in the Trials journal. About half (51%) of included studies 
were investigating behavioural intervention strategies. Most of the protocols (39%) 
were targeting a combination of HIV testing, linkage to and retention in care followed 
by HIV testing and risk reduction interventions  in 22% of the protocols. Most studies 
(62%) were planned to be conducted in Africa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 PRISMA flow diagram 
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3.3 Overall reporting of SPIRIT checklist recommendations  
The included protocols reported a mean of 32 (SD 5) checklist items. Study findings 
on SPIRIT items reported in included protocols are summarised below and 
presented in Figure 2. 
 
3.3.1 Administrative information  
All protocols reported a descriptive title as well as the roles of protocol contributors. 
Almost all protocols 75/79 (95% ) reported their trial registration number while none 
of the protocols included the WHO trial registration data set. The protocol version 
was reported in very few 5/79 (6%) protocols. The sources of funding were reported 
in almost all 76/79 (96%) protocols. However, only about half 36/79 (46%) of 
protocols reported on whether the study funders had any role or ultimate authority 
over any study activities. The least reported item was the study coordinating 
committees which was reported in a fifth 16/79 (20%) of the protocols.  
3.3.2 Introduction 
The introduction was generally well reported in all 79 protocols providing study 
justifications, objectives as well as the trial designs.  
3.3.3 Methods: Participants, interventions and outcomes 
Protocols routinely included participant, intervention and outcome information with all 
79 of them reporting eligibility criteria, study setting, sufficiently detailed descriptions 
of interventions, study outcomes, participant schedules and study recruitment 
strategies. Sample size calculations were reported by almost all 76/79 (96%) 
protocols. Almost three quarters 56/79 (71%) of protocols reported on intervention 
adherence strategies. Concomitant care was reported by 33/79 (42%) of protocols, 
whilst only 9/79 (11%) protocols reported criteria for modifying or discontinuing 
interventions. 
3.3.4 Methods: Assignment of interventions 
With respect to allocation of interventions, detailed methods of allocation sequence 
generation and concealment of the sequence were reported in 57/79 (72%) and  
46/79 (58%) of protocols respectively, with about 44/79 (56%) reporting on 
individuals involved in the randomization processes. Almost 48/79 (61%) reported on 
the blinding status of the trial, whilst only 5/59 (8%) of the blinded trials reported on 
circumstances when emergency unblinding would be permissible. 
Stellenbosch University  https://scholar.sun.ac.za
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Table 1. Characteristics of included protocols (n = 79) 
Characteristic  n (%) 
Period of protocol 
publication Pre-SPIRIT 2008 - 2013 20 (25) Post-SPIRIT 2014 - 2018 59 (75) 
Funding  Industry  2    (2) 
Non-industry 74  (94) 
Not reported 3    (4) 
Study setting Single-site 16  (20) 
Multi-site 63  (80) 
Geographical region Africa 49  (62) 
 Asia 10  (13) 
 N. America 17  (21) 
 Europe  2    (3) 
 Middle East 1    (1) 
Protocol intervention 
category 
HIV prevention 25  (32) 
HIV prevention and treatment 13  (16) 
HIV treatment and care 41  (52) 
Protocol Intervention target Adherence and retention in care 14   (18) 
Risk reduction and Testing 17   (22) 
Testing, linkage and retention in care 31   (39) 
Retention in care 8     (10) 
 Therapy initiation, option and switch 5     (6) 
 Immune boost 2     (3) 
 Opportunistic infection prophylaxis 1     (1) 
 Palliative care 1     (1) 
Publishing journal BMC Health Services Research 3    (4) 
BMC Medical Informatics and 
Decision making 1    (1) 
BMC Medical Research 
methodology 1    (1) 
BMC Public health 7    (9) 
BMC infectious diseases 9    (11) 
BMJ Open 5    (6) 
Contemporary clinical trials 3    (4) 
Implementation Science 6    (8) 
Iranian Journal of Psychiatry 1    (1) 
J Acquired Immune Defic. Syndr. 3    (4) 
JMIR 12  (15) 
Trials  28  (35) 
Publishing journal SPIRIT 
endorsement status 
Yes  72  (91) 
No 7    (9) 
Funding: main trial sponsor 
SPIRIT endorsement: based on listing on SPIRIT endorsement website [11]. 
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3.3.5 Methods: Data collection, management and analysis 
All 79 protocols reported plans for trial data collection but about two thirds 54/79 
(68%) reported on their data management plans. Over half 44/78 (56%) of protocols 
reported their plans to promote participant retention and complete follow-up of 
participants. Almost all protocols reported the statistical methods for primary and 
secondary outcome analysis 78/79 (99%) and any planned additional analyses 77/79  
(98%). However, 55/79 (70%) defined the analysis population relating to protocol 
non-adherence.  
3.3.6 Methods: Monitoring 
Data monitoring plans were poorly reported with 31/79 (39%) reporting on Data 
Monitoring Committees (DMC), just under a third 22/75 (29%) reporting on planned 
interim analyses and trial stopping guidelines and only 12/79 15%) reporting on 
periodic (non-routine) trial auditing procedures and frequency. Evaluation of solicited 
and spontaneously reported harms was reported in just under half 37/78 (47%) of 
study protocols. 
3.3.7 Ethics and dissemination 
Ethics approvals and plans for seeking such approvals were reported in almost all 
77/79 (97%) of protocols while almost a quarter 18/79 (23%) reported on plans for 
communicating important modifications to the trial protocol. All 76/76 (100%) 
protocols reported on general consent and assent. However, just under half 5/11 
(45%) of the protocols which reported on planned ancillary studies provided 
additional consent provisions for the use of participant data and specimens in  future 
studies. Conflicts of interest were highly declared 75/79 (95%) while protection of 
confidentiality was reported in about 70% (55/79) of protocols. Low reporting was 
observed on issues regarding access to final trial dataset 25/79 (32%), ancillary and 
post-trial care for participants 10/78 (13%), trials results dissemination plans 26/79  
(33%) , authorship guidelines 7/79 (9%) and plans for making trial dataset and full 
protocol available to the public 16/79 (20%). 
3.3.8 Appendices 
A few 7/76 (9%) protocols included a model informed consent form as an appendix. 
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Figure 2 Percentage of protocols reporting individual items was calculated with adjusted 
denominators (n-x), x being the number of protocols for which that particular checklist item was 
judged to be inapplicable and n=79 protocols. 
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3.4 Factors associated with number of  SPIRIT checklist items reported 
Generalised estimation equations results for the protocol characteristics associated 
with number of reported items are presented in Table 2. We excluded the funding 
source from the multivariate model. This was because of significant imbalance in the 
numbers of protocols since almost all, 74/79 (94%) of included studies were 
non-industry funded, with only 2 studies that were industry funded. We also excluded 
SPIRIT endorsement because most protocols, 72/79 (91%) were published in 
journals which endorsed the guideline at the time this study was conducted. The full 
GEE model output is attached as Appendix G. 
 
Table 2. Univariate and multivariate generalized estimation equations model results 
Protocol 
characteristic 
Unadjusted analysis Adjusted analysis 
Incidence 
Rate Ratio 
95% CI p-
value 
Incidence 
Rate Ratio 
95% CI p-
value 
Published 
2014 - 2018 
versus 2008 - 
2013  
1.05 0.98 to 1.13 0.15 1.05 0.98 to 1.12 0.20 
Multi-site vs 
single-site trial 
1.02 0.91 to 1.15 0.71 1.01 0.91 to 1.12 0.81 
Intervention 
HIV prevention 
vs 
HIV prevention 
and treatment 
1 
(reference) 
1.03 
 
0.96 to 1.11 
 
0.45 
1 
(reference) 
1.03 
 
0.93 to 1.14 
 
0.58 
HIV prevention 
vs  
HIV treatment 
and care 
1 
(reference) 
1.00 
 
0.95 to 1.05 
 
1.00 
1 
(reference) 
1.01 
 
0.94 to 1.09 
 
0.73 
 
None of the covariates were associated with number of SPIRIT checklist items that 
were reported in the study protocol. 
4. Discussion 
4.1 Summary of findings 
Overall, reporting of SPIRIT items in the included protocols was above average. A 
study conducted on the SPIRIT 2013 checklist by Kyte et. al produced similar results 
showing that about a third of checklist items were missing from protocols [9]. The 
administrative information and introduction sections were generally very well 
reported except for the WHO recommended trial registration data set, protocol 
version and roles of study committees and sponsors. Absence of information on 
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study coordinating committees results in reviewers being unable to appreciate the 
expertise of the individuals overseeing the safety of participants as well as other 
quality aspects of the study. The role of study sponsors could potentially be 
associated with bias if the sponsor controls key aspects of the trial [12].   
 
We found that methodological details in published HIV clinical trial protocols are still 
quite deficient five years after the publication of the SPIRIT guideline. These results 
are in agreement with available empirical evidence on deficient important 
methodological aspects of protocols [9 ,7]. Of note, allocation concealment and 
implementation of randomization were missing in about half of protocols. These 
elements are associated with the successful implementation of randomisation, the 
core procedure that renders randomised controlled trials to be regarded as the ‘gold 
standard’ in clinical research. Poor implementation of randomisation could result in 
selection bias creeping into studies thus undermining the internal validity of the trial, 
often resulting in exaggerated effect sizes [13].  
 
Also poorly reported was the analysis population relating to protocol non-adherence. 
This was not reported in about a third (30%) of the protocols. Analysis by intention to 
treat  is recommended for randomised controlled trials as it gives more conservative 
view of the intervention effects [14]. It is important that this item be reported in 
protocols so as to enable assessment of protocols for selection bias and attrition bias 
depending on the chosen primary analysis population. 
 
It is important to note that though methodological elements were not adequately 
reported in the protocols, their implementation during trial conduct may be 
satisfactory if they are adequately explained in procedure manuals. However these 
manuals are normally unavailable for the various stakeholders reviewing protocols 
and research reports, hence the need to adequately and consistently report them in 
all trial documents. 
 
Data quality is key to collection of valid and reliable trial data. In the included 
protocols, though data collection plans were reported in all protocols, about two 
thirds of these reports were incomplete. The missing information related to the data 
quality processes, and references to where data collection forms could be accessed. 
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The data management item also missed key data security and quality processes. 
Data collection and management flaws can introduce bias into the study thus 
reducing internal validity of the trial. 
 
Periodic independent trial auditing is an important check that verifies and ensures 
that trial conduct is being done according to standard policies and procedures, 
including basic good clinical practices. This aspect was reported in only 15% of trial 
protocols despite its importance in ensuring participant protection and data integrity. 
Other aspects of data monitoring such as Data Monitoring Committees and interim 
analyses plans were also poorly reported possibly due to the minimal risk presented 
by the interventions in the trials, since the majority were behavioural in nature.  
 
Poor reporting of the study dissemination plans has implications on the ethical 
obligation to publish research results and transparency of research. Lack of 
dissemination plans also drives publication bias as null and negative results are less 
likely to be submitted for publication [15]. 
 
We compared completeness of trial protocols published prior to, and after the 
publication to SPIRIT guidelines. We found statistically insignificant difference in the 
reporting of protocols between the two time periods. This could be due to variations 
in implementation policies of the SPIRIT statement by the different publishing 
journals and awareness of the existence of the guidelines by protocol authors. Thus, 
the guideline did not have a significant association with protocol completeness on 
the included HIV protocols since its publication in comparison to the time prior to its 
publication. 
 
The results of this study show that there is room for improvement in the reporting of 
published HIV trial protocols which should be considered by HIV trialists as they 
publish their protocols. This is more so important given the pandemic nature of HIV 
where flawed study designs may impact health at the world population level. We also 
noted the unavailability of published protocols investigating pharmacological agents 
in the databases searched. This could be related to the fact that these are mostly 
industry funded. However, all protocols should be published in order to fulfil the 
research transparency agenda. 
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However, the lack of compliance is not surprising given that there are varying levels 
of guideline endorsement and implementation. Currently the SPIRIT statement has 
been endorsed by various journals, regulators, research funders, trial groups as well 
as patient groups [11]. Levels of endorsement range from general statements of 
support, investigator encouragement and explicit requirements to use the checklist 
[16]. Strong endorsement policy with intentional implementation is likely to result in 
more improvement in the completeness and reporting of all checklist items [17]. This 
will ensure that HIV trials are of high scientific rigor given the significance of the 
disease. We recommend a bigger study which incorporates the individual journal 
endorsement level with respect to SPIRIT implementation. In addition, a follow-up 
study comparing the reporting of the protocols against completed study reports 
would be helpful to see if any discrepancies exist. It will also be worthwhile to 
conduct a survey on  the SPIRIT guideline implementation strategies that are being 
utilised by journals. 
 
4.2 Strengths and weaknesses 
The main strength of the study is the use of systematic methods in conducting the 
survey. The study included protocols from periods prior to  and post SPIRIT 
publication which allowed for a comparison of the two periods. 
 
The study had various limitations. Though we searched multiple databases, our 
search likely missed other protocols which may be published in journals which are 
not indexed in these databases. Overall, this limits the generalizability of these study 
results in the HIV field. 
 
The use of a composite score assumes that each of the 51 items on the SPIRIT 
checklist are equally important. This may not be the case as readers perspectives 
vary. In addition, the different research biases associated with the checklist items 
variably affect trial results. However, we decided to look at all the SPIRIT checklist 
items so as to get a general sense of adherence of protocols to the checklist as a 
whole. 
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However, we did not account for the journal endorsement status at the actual time 
when the included protocol was published. It is possible that some protocols were 
published in the study defined post-SPIRIT era, prior to the journals endorsing, or 
actively implementing the SPIRIT statement. This could have biased the results 
towards the null. 
5. Conclusion 
There is need for improvement in the reporting of recommended SPIRIT 2013 items 
in HIV intervention protocols. Detailed methodological aspects relating to intervention 
allocation, blinding, data management, study monitoring and dissemination policy 
information were often missing in the protocols. We recommend future research 
comparing HIV trial protocols and reports after trial conduct, as well as on the 
awareness of SPIRIT guidelines among researchers.  
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Appendix A: PRISMA checklist
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  6 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
7 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  9,10 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
10 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
Not 
registered 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as criteria for 
eligibility, giving rationale.  
11 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with 
study authors to identify additional studies) in the search and date last searched.  
11 
Search  8 Present full electronic search strategy for at least one database, including any limits 
used, such that it could be repeated.  
37 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis).  
12 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
12 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) 
and any assumptions and simplifications made.  
40 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
n/a 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  n/a 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I2) for each meta-analysis.  
n/a 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
n/a 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
13 
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From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, 
with reasons for exclusions at each stage, ideally with a flow diagram.  
13,14 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, 
PICOS, follow-up period) and provide the citations.  
14,45 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
n/a 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence intervals, 
ideally with a forest plot.  
n/a 
Synthesis of results  21 Present the main results of the review. If meta-analyses are done, include for each, 
confidence intervals and measures of consistency" 
15-19 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  n/a 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, 
meta-regression [see Item 16]).  
19 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main 
outcome; consider their relevance to key groups (e.g., healthcare providers, users, and 
policy makers).  
19 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level 
(e.g., incomplete retrieval of identified research, reporting bias).  
22 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
23 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of 
data); role of funders for the systematic review.  
23 
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CONSORT Consolidated Standards of Reporting Trials 
IEC   Independent Ethics Committee 
NIHR-HTA National Institutes of Health Research- Health Technology Assessment 
PRO  Patient Reported Outcomes 
PRISMA-P Preferred Reporting Items for Systematic review and Meta-Analysis Protocols 
RCT  Randomised Controlled Trial 
SPIRIT Standard Protocol Items: Recommendations for Interventional Trials  
 
Keywords 
HIV treatment efficacy, HIV prevention efficacy, randomised controlled trials, clinical trials, 
protocol reporting, protocol completeness, SPIRIT guideline, SPIRIT checklist 
 
Introduction 
A clinical trial protocol is an important document for trial implementation. The Standard 
Protocol Items: Recommendations for Interventional Trials (SPIRIT) guideline specifies that a 
protocol should provide sufficient detail to enable understanding of the background, rationale, 
objectives, study population, interventions, methods, statistical analyses, ethical 
considerations, dissemination plans and administration of the trial. It should be detailed enough 
to allow replication of key aspects of trial methods and conduct. The level of clarity and 
transparency should allow proper appraisal of the scientific and ethical rigor from ethics 
approval all the way to dissemination of results [5]. Beyond study implementation, the protocol 
is used by systematic reviewers and journal editors for assessment of bias and peer review 
respectively [6].  
Given the diversity of stakeholders who use protocols, it is therefore imperative that the content 
reported in a trial protocol be both transparent and adequately detailed to sufficiently address 
the needs of all the users of protocols. However, there is empirical evidence on the lack of 
information such as unclear descriptions of allocation concealment in 83% of protocols 
reviewed, which potentially introduces selection bias during trial conduct [7]. Sample size and 
statistical plans were also found to be discrepant between protocol and final study publications 
in 82% of studies, which is associated with biased trial results and conclusions[3]. Biased 
results and conclusions may result in ill-informed policies to the detriment of human health. 
Poor reporting of methodological details may necessitate protocol amendments which 
increases the costs of the trial. 
The above empirical evidence underscores the need for guidance on good protocol reporting. 
Several guidelines for protocol writing are available and a review of these guidelines in 2012 
revealed great variation in the scope and recommendations given [6]. The review also showed 
that the guidelines lacked citation of broad stakeholder involvement in their development or 
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the use of empirical evidence to support their recommendations. To address these deficiencies, 
the SPIRIT initiative was launched bringing together international stakeholders, to 
systematically produce a comprehensive evidence informed guideline to help improve the 
completeness and transparency of trial protocols. The SPIRIT guideline was published in 
January 2013 as a 33-item evidence based checklist for high quality protocol content[8]. An 
explanation and elaboration document was also published with important information and 
examples for each checklist item[5].    
Availability of the SPIRIT guideline alone does not guarantee improvement in the quality of 
protocols. Turner et al [18] showed 85% relative benefit of endorsement of the Consolidated 
Standards of Reporting Trials (CONSORT) statement on completeness of randomised trial 
reports when compared with journals that did not endorse the CONSORT guideline. The 
various stakeholders such as trial investigators, research sponsors, ethics committees, trial 
registries and journal editors need to endorse and intentionally implement the guideline in order 
to see the outcome of improved protocol quality. Currently, the SPIRIT guideline has been 
endorsed by various journals, regulators, research funders, trial groups as well as patient 
groups[11]. Implementation of the SPIRIT guidelines in protocol development is expected to 
ultimately increase the robustness of medical literature used to inform health care decisions. 
There are few published studies that have measured the impact the SPIRIT guidelines on 
protocol reporting quality. A study evaluating reporting quality of protocols in the National 
Institute for  Health Research Health Technology Assessment (NIHR-HTA) database revealed 
that on average 63% of SPIRIT recommendations were reported [9]. However, this study was 
done seven months after the publication of SPIRIT guideline, hence the impact may not have 
been realised at that time. There is a published protocol for a systematic review that will assess 
planned statistical methods for surgical protocols using the SPIRIT guidelines [19]. This study 
will focus on specific areas of the SPIRIT checklist hence it does not give the overall 
completeness of the whole protocol. Given the highlighted importance of protocol reporting 
and how different sections of the protocol may potentially introduce bias, more studies are 
needed to assess the completeness of protocols in different research fields against the full 
SPIRIT checklist.  
HIV is a fast evolving field of public health concern, with various interventions and strategies 
being tested in treatment, prevention and care services and procedures. There is no published 
data on protocol completeness since the publication of the SPIRIT guidelines. Our study seeks 
to measure the adherence to SPIRIT guidelines, of randomised controlled trial protocols on 
HIV interventions evaluating the efficacy or effectiveness of treatments, services or 
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procedures. A study focusing on protocol quality in this area will be useful to HIV research 
stakeholders as it will provide feedback on quality of protocols and highlight areas of 
improvement. The results will be disseminated in peer-reviewed publications. 
Research question and objectives 
Research question 
What is the status of protocol reporting quality for HIV randomised controlled trial protocols 
evaluating the efficacy or effectiveness of treatments, prevention strategies and services or 
procedures?  
Research objectives 
1] To determine how many items of SPIRIT guideline are documented in the trial protocol,  
2] To determine the association of protocol characteristics with the number of items of the 
SPIRIT guideline reported in trials protocols. 
Methods  
Study design 
The study will be systematic survey of protocols for HIV evaluating the efficacy or 
effectiveness of treatments, prevention strategies and care services or procedures for 
completeness based on the SPIRIT checklist recommendations. The protocol will follow the 
Preferred Reporting Items for Systematic review and Meta-Analysis Protocols (PRISMA-P) 
checklist recommendations [20]. 
Eligibility criteria 
 Eligible RCT study protocols should meet the following criteria: 
• It should be a protocol or methods paper for an RCT (cluster, parallel, factorial or 
pragmatic design) and should not report trial outcomes. 
• The RCT must investigate efficacy or effectiveness of pharmacological or non-
pharmacological agents for HIV treatment, care and prevention. 
• The RCT must be for HIV related services or procedures 
• The RCT should not be a pilot or feasibility study to determine feasibility of 
conducting an efficacy study. 
• The protocols should be published between 2008 and 2018. 
Search strategy 
We will search the following databases MEDLINE (PubMED), EMBASE(OVID) and Cinahl 
(EBSCOHost) and clinical trials registries listed on the SPIRIT website  [21] for protocols. The 
search strategy will include the terms randomized controlled trial, HIV and protocol and their 
synonyms. Reference lists of all included protocols will be manually searched to ensure that 
there are no relevant study protocols that have been missed by the database search. 
Data screening, extraction and synthesis 
Two reviewers will independently screen titles and abstracts from the search output and extract 
data of eligible trial protocols. Disagreements will be resolved through consensus. Data 
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regarding compliance of the protocols with each of the 51 SPIRIT checklist items (all 
subsections of the 33 items on the checklist are counted individually) will be extracted using a 
standard data extraction form. We will also extract information on whether: the journal/ trial 
registry endorses the SPIRIT guideline, the protocol was for a single or multi-centre study, the 
protocol was for an intervention for treatment, care, prevention, services or procedures related 
to HIV, the study was industry or non-industry funded and year of publication 2008 -2013 
(2008- 2013 pre-SPIRIT era; 2014 -2018 post SPIRIT era).  
Sample size 
Sample size will be calculated based on a score of the number of items of the SPIRIT checklist 
reported in the trial protocols. A survey assessing the quality of reporting randomised protocols 
in the NIHR HTA programme database found that studies reported a mean score of 32  SPIRIT 
checklist items, range 16-41 (standard deviation 6.25) [9].  To estimate a similar mean score, 
(with a 95% confidence level of ±3 scores) of items of the SPIRIT guideline documented in 
published randomized trial protocols for prevention and treatment of HIV, we require 37 
protocols. We will test the association of five potential factors (listed under data extraction and 
synthesis) with the number of items of the SPIRIT checklist reported in published protocols. 
After an upward adjustment of 10 studies for each factor included in the analysis, 87 protocols 
will be required. We will randomly select protocols from the eligible protocols list, if we find 
more eligible protocols than the required sample size. 
Statistical analysis 
We will summarize the characteristics of included protocols using mean (standard deviation) 
or median (interquartile range) for continuous variables depending on the distribution, and 
categorical data using count (percent). We will use count (percent) to summarize items of 
SPIRIT guideline documented in published protocols. We will use generalized estimation 
equations (GEE), that assume a Poisson distribution and an unstructured covariance matrix to 
explore factors associated with the number of items of SPIRIT guideline complied with, in 
protocol reports. Incidence rate ratio estimates will be reported for the GEE model. We will 
report estimates with the corresponding 95% confidence interval (CI). Alpha of 0.05 will be 
used as the criterion for statistical significance. We will control for the following factors in our 
models: 1) whether the journal or trial registry endorses the SPIRIT guideline, 2) whether the 
proposed study was a single or multi-site, 3) whether the proposed study was on prevention or 
treatment of HIV disease, 4) year of publication (2008 to 2012 (pre-SPIRIT) and 2013 to 2018 
(post SPIRIT) and 5) whether the study was industry funded or non-industry funded. All 
analyses will be done using STATA version 15. 
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Ethical considerations 
For this type of study formal ethics approval is not required. Funding sources will have no role 
in study design; analysis and interpretation of data; in the writing of the report; and in the 
decision to submit the article for publication. 
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The results of this study will be disseminated in peer reviewed publications and presented at 
conferences. 
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Protocol Summary of changes 
Project title: Completeness of HIV treatment and prevention trial protocols: a protocol for a systematic survey 
 
 
Summary of changes from Protocol version 1.0 dated April 24, 2018 to Protocol version 2.0 dated 
May 24, 2018 
 
Protocol Version 1.0 
Dated April 24, 2018 
Protocol Version 2 
dated May 24, 2018 
Rationale 
Title page 1 
Completeness of HIV treatment 
and prevention trial protocols: a 
protocol for a systematic survey 
 
Title page 1 
Completeness of HIV 
intervention trial protocols: a 
protocol for a systematic survey 
Title changed to match 
broader scope of trial 
Introduction page 5 
HIV treatment and prevention is 
a fast evolving field of public 
health concern with no 
identified published data on 
protocol completeness. A study 
focusing on protocol quality in 
this area will be useful to HIV 
research stakeholders as it will 
provide feedback on quality of 
protocols and highlight areas of 
improvement. The results will 
be disseminated in peer-
reviewed publications. 
 
Introduction page 5 
HIV is a fast evolving field of 
public health concern, with 
various interventions and 
strategies being tested in 
treatment, prevention and care 
services and procedures. There 
is no published data on protocol 
completeness since the 
publication of the SPIRIT 
guidelines. Our study seeks to 
measure the adherence to 
SPIRIT guidelines, of 
randomised controlled trial 
protocols on HIV interventions 
evaluating the efficacy or 
effectiveness of treatments, 
services or procedures. 
We reframed the scope of the 
study following advice from 
search specialist and Prof T. 
Lehana pertaining to 
availability of published study 
protocols. 
Research question page 5 
What is the status of protocol 
reporting quality for HIV 
treatment efficacy and 
prevention efficacy trial 
protocols? 
 
Research question page 5 
What is the status of protocol 
reporting quality for HIV 
randomised controlled trial 
protocols evaluating the efficacy 
or effectiveness of treatments, 
prevention strategies and 
services or procedures? 
Research scope broadening 
Study design page 6 
The study will be systematic 
survey of protocols for HIV 
treatment efficacy and 
prevention efficacy for 
completeness based on the 
SPIRIT checklist 
recommendations. 
Study design page 6 
The study will be systematic 
survey of protocols for HIV 
evaluating the efficacy or 
effectiveness of treatments, 
prevention strategies and care 
services or procedures for 
completeness based on the 
SPIRIT checklist 
recommendations. 
Research scope broadening 
Eligibility criteria page 6 
It should be a protocol or 
methods paper for an RCT, 
cluster RCT or other RCT 
Eligibility criteria page 6 
It should be a protocol or 
methods paper for an RCT 
(cluster, parallel, factorial or 
Refining eligibility criteria to 
match new scope of study 
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design and should not report 
trial outcomes. 
The RCT must investigate 
efficacy of pharmacological 
agents, in any dosage form, for 
HIV treatment or prevention. 
 
pragmatic design) and should 
not report trial outcomes. 
The RCT must investigate 
efficacy or effectiveness of 
pharmacological or non-
pharmacological agents for HIV 
treatment, care and prevention. 
The RCT must be for HIV 
related services or procedures 
 
Search strategy page 6 
The search strategy will include 
the terms randomized control*, 
RCT, intervention study, HIV 
disease, HIV/AIDS, HIV 
infection immunodeficiency, 
immune-suppression, treatment 
efficacy, prevention efficacy 
Search strategy page 6 
The search strategy will include 
the terms randomized controlled 
trial, HIV and protocol and their 
synonyms 
Refining of search strategy 
Data screening, extraction 
and synthesis page 6 
We will also extract information 
on whether: the journal/ trial 
registry endorses the SPIRIT 
guideline, the protocol was for a 
single or multi-centre study, the 
protocol was for an intervention 
on treatment, care or 
prevention of HIV, the study 
was industry or non-industry 
funded and year of publication 
2008 -2013 (2008-January 
2013 pre-SPIRIT era; February 
2013 -2018 post SPIRIT era).  
 
Data screening, extraction 
and synthesis page 6 
We will also extract information 
on whether: the journal/ trial 
registry endorses the SPIRIT 
guideline, the protocol was for a 
single or multi-centre study, the 
protocol was for an intervention 
for treatment, care, prevention, 
services or procedures related 
to HIV, the study was industry 
or non-industry funded and year 
of publication 2008 -2013 
(2008- 2013 pre-SPIRIT era; 
2014 -2018 post SPIRIT era). 
Revised definition of pre and 
post SPIRIT era to allow for 
transition period after 
guideline publication. 
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Appendix C: Search strategy 
MSc Clin Epi research project 
Title: What is the adherence to SPIRIT guidelines of randomised controlled trial protocols on HIV 
interventions evaluating the efficacy or effectiveness of treatments, services or procedures?  
Electronic databases/registries to search 
• Medline (PubMed) 
• CENTRAL (Wiley Cochrane Library) 
• EMBASE (Ovid) 
• Africa-Wide Information (EBSCOhost)  
• LILACS (Virtual Health Library)  
• Web of Science – Core Collection 
• ClinicalTrials.gov (https://www.clinicaltrials.gov/)  
Medline (PubMed) 
#1 Search All Fields (HIV OR hiv-1 OR hiv-2* OR hiv1 OR hiv2 OR hiv infect* OR human 
immunodeficiency virus OR human immune deficiency virus OR human immuno-deficiency virus OR 
human immune-deficiency virus OR ((human immun*) AND (deficiency virus)) OR acquired 
immunodeficiency syndromes OR acquired immune deficiency syndrome OR acquired immuno-
deficiency syndrome OR acquired immune-deficiency syndrome OR ((acquired immun*) AND 
(deficiency syndrome)) OR HIV/AIDS) 
#2 Search (HIV infections [MeSH] OR HIV [MeSH]) 
#3 (#1 OR #2) 
#4 protocols OR proposals OR protocol OR proposal OR “Clinical Protocols” [Mesh] 
#5 randomized controlled trial [pt] OR controlled clinical trial [pt] OR random [Title/Abstract] OR 
randomized [Title/Abstract] OR randomised [Title/Abstract] OR randomly [Title/Abstract] OR 
randomize [Title/Abstract] OR randomise [Title/Abstract] OR trial [Title/Abstract] OR experimental 
[Title/Abstract] OR experiment OR placebo [Title/Abstract] OR clinical trials as topic [mesh: noexp] 
#6 #3 AND #4 AND #5 
#7 animals [Mesh] NOT humans [Mesh] 
#8 #6 NOT #7 
Search date: 29 May 2018 
No date limitations 
Number of search results retrieved: 1871 
 
CENTRAL (Wiley Cochrane Library) 
#1 HIV or hiv-1 or hiv-2* or hiv1 or hiv2 or hiv infect* or human immunodeficiency virus or human 
immune deficiency virus or human immuno-deficiency virus or human immune-deficiency virus  
#2 (human immun*) and (deficiency virus) or acquired immunodeficiency syndromes or acquired 
immune deficiency syndrome or acquired immuno-deficiency syndrome or acquired immune-
deficiency syndrome 
#3 acquired immun* and deficiency syndrome  
#4 "HIV/AIDS" 
#5 MeSH descriptor: [HIV] explode all trees 
#6 MeSH descriptor: [HIV Infections] explode all trees 
#7 #1 or #2 or #3 or #4 or #5 or #6 
#8 protocols or proposals or protocol or proposal 
#9 MeSH descriptor: [Clinical Protocols] explode all trees 
#10 #8 or #9 
#11 randomized controlled trial or controlled clinical trial or random OR randomized or randomised or 
randomly or randomize or randomise or trial or experimental or experiment or placebo 
#12 MeSH descriptor: [Clinical Trials as Topic] explode all trees 
#13 MeSH descriptor: [Randomized Controlled Trials as Topic] explode all trees 
#14 MeSH descriptor: [Controlled Clinical Trials as Topic] explode all trees 
#15 #11 or #12 or #13 or #14 
#16 #7 AND #10 AND #15 
#17 MeSH descriptor: [Humans] explode all trees 
#18 MeSH descriptor: [Animals] explode all trees 
#19 #18 not #17 
#20 #16 not #19 
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Search date: 29 May 2018 
No date limitations 
Number of search results retrieved: 1083 
 
EMBASE (Ovid) 
-------------------------------------------------------------------------------- 
1     *Human immunodeficiency virus/  
2     *Human immunodeficiency virus infection/  
3     (human immunodeficiency virus or human immune deficiency virus or human immuno-deficiency 
virus or human immune-deficiency virus).ab.  
4     (human immunodeficiency virus or human immune deficiency virus or human immuno-deficiency 
virus or human immune-deficiency virus).ti.  
5     (hiv-1* or hiv-2* or hiv1 or hiv2).ti. or (hiv-1* or hiv-2* or hiv1 or hiv2).ab.  
6     1 or 2 or 3 or 4  
7     (acquired immunodeficiency syndromes or acquired immune deficiency syndrome or acquired 
immuno-deficiency syndrome or acquired immune-deficiency syndrome).ti. or (acquired 
immunodeficiency syndromes or acquired immune deficiency syndrome or acquired immuno-
deficiency syndrome or acquired immune-deficiency syndrome).ab. 
8     (acquired immun* and deficiency syndrome).ti. or (acquired immun* and deficiency 
syndrome).ab.  
9     6 or 7 or 8  
10     (protocols or proposals or protocol or proposal).ab. or (protocols or proposals or protocol or 
proposal).ti.  
11     controlled clinical trial.mp. or Controlled Clinical Trial/  
12     randomized controlled trial.mp. or Randomized Controlled Trial/  
13     (randomized or randomised or randomly or randomize or randomise or trial or experimental or 
experiment or placebo).ab. or (randomized or randomised or randomly or randomize or randomise or 
trial or experimental or experiment or placebo).ti.  
14     clinical protocol/  
15     10 or 14  
16     11 or 12 or 13  
17     9 and 15 and 16  
18     animal/  
19     human/  
20     18 not 19  
21     17 not 20  
Search date: 1 June 2018 
No date limitations 
Number of search results retrieved: 1080 
 
Africa-Wide Information (EBSCOhost)  
#1 All fields: (HIV OR hiv-1 OR hiv-2* OR hiv1 OR hiv2 OR hiv infect* OR human immunodeficiency 
virus OR human immune deficiency virus OR human immuno-deficiency virus OR human immune-
deficiency virus OR ((human immun*) AND (deficiency virus)) OR acquired immunodeficiency 
syndromes OR acquired immune deficiency syndrome OR acquired immuno-deficiency syndrome OR 
acquired immune-deficiency syndrome OR ((acquired immun*) AND (deficiency syndrome)) OR 
HIV/AIDS) 
#2 All fields: (protocols OR proposals OR protocol OR proposal) 
#3 All fields: (randomized controlled trial or controlled clinical trial or random OR randomized or 
randomised or randomly or randomize or randomise or trial or experimental or experiment or placebo) 
#4 #1 AND #2 AND #3 
Search date: 31 May 2018 
No date limitations 
Number of search results retrieved: 459 
 
LILACS (Virtual Health Library)  
HIV$ OR immune deficiency OR immune-deficiency OR immunedeficiency OR HIV/AIDS [Words] and 
protocols OR proposals OR protocol OR proposal [Words] and random$ OR trial OR blind$ OR 
control$ OR compar$ [Words] 
Search date: 31 May 2018 
Stellenbosch University  https://scholar.sun.ac.za
                                                           Page 39 of 76 
 
No date limitations 
Number of search results retrieved: 168 
 
Web of Science – Core Collection 
((TOPIC: (((((HIV* OR "HIV infect*") OR immune deficiency) OR immune-deficiency) OR 
immunodeficiency) OR HIV AIDS) AND TOPIC: (((protocols OR proposals) OR protocol) OR 
proposal)) AND TOPIC: (((((((((((randomized controlled trial OR controlled clinical trial) OR random) 
OR randomized) OR randomised) OR randomly) OR randomize) OR randomise) OR trial) OR 
experimental) OR experiment) OR placebo)) 
Timespan: All years. Indexes: SCI-EXPANDED, SSCI, CPCI-S. 
Search date: 31 May 2018 
No date limitations 
Number of search results retrieved: 2139 
 
ClinicalTrials.gov (clinicaltrials.gov)  
(protocols OR proposals OR protocol OR proposal) | Interventional Studies | (HIV OR immune 
deficiency OR immune-deficiency OR immunedeficiency OR HIV/AIDS) 
Search date: 31 May 2018 
No date limitations 
Number of search results retrieved: 576 
 
In summary: 
From all the databases, I imported a total of 7283 records (459 Africa-wide + 1082 CENTRAL + 576 
clinicaltrials.gov + 1080 EMBASe +1946 PubMed + 2139 Web of Science) into Endnote. 
I have de-duplicated the findings: 2412 duplicates were removed 
Numbers of records to screen: 4871  
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Appendix D: Study checklist 
Table B1. Study checklist for data collection 
REF ID Number  Extracted by (initials) 
Topic Item # SPIRIT Checklist item description Vote 
Yes 
(1) 
No 
(0) 
N/A 
(leave 
blank) 
 Administrative information 
Title  1 Descriptive title identifying the study design, population, 
interventions, and, if applicable, trial acronym  
   
 
 
Trial registration 
2a Trial identifier and registry name. If not yet registered, name of 
intended registry  
   
2b All items from the World Health Organization Trial Registration 
Data Set  
   
Protocol version 3 Date and version identifier    
Funding  4 Sources and types of financial, material, and other support     
 
 
 
 
Roles and 
responsibilities 
5a Names, affiliations, and roles of protocol contributors    
5b Name and contact information for the trial sponsor     
5c Role of study sponsor and funders, if any, in study design; 
collection, management, analysis, and interpretation of data; 
writing of the report; and the decision to submit the report for 
publication, including whether they will have ultimate authority over 
any of these activities  
   
5d Composition, roles, and responsibilities of the coordinating centre, 
steering committee, endpoint adjudication committee, data 
management team, and other individuals or groups overseeing the 
trial, if applicable (see Item 21a for data monitoring committee)  
   
 Introduction 
Background and 
rationale 
6a Description of research question and justification for undertaking 
the trial, including summary of relevant studies (published and 
unpublished) examining benefits and harms for each intervention  
   
6b Explanation for choice of comparators     
Objectives 7 Specific objectives and hypotheses    
Trial design 8 Description of trial design including type of trial (eg, parallel group, 
crossover, factorial, single group), allocation ratio, and framework 
(eg, superiority, equivalence, noninferiority, exploratory)  
   
 Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, academic 
hospital) and list of countries where data will be collected. 
Reference to where list of study sites can be obtained  
   
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, 
eligibility criteria for study centres and individuals who will perform 
the interventions (eg, surgeons, psychotherapists)  
   
 
 
Interventions 
11a Interventions for each group with sufficient detail to allow 
replication, including how and when they will be administered  
   
11b Criteria for discontinuing or modifying allocated interventions for a 
given trial participant (eg, drug dose change in response to harms, 
participant request, or improving/worsening disease)  
   
11c Strategies to improve adherence to intervention protocols, and any 
procedures for monitoring adherence (eg, drug tablet return, 
laboratory tests)  
   
11d Relevant concomitant care and interventions that are permitted or 
prohibited during the trial  
   
Outcomes  12 Primary, secondary, and other outcomes, including the specific 
measurement variable (eg, systolic blood pressure), analysis 
metric (eg, change from baseline, final value, time to event), 
method of aggregation (eg, median, proportion), and time point for 
each outcome. Explanation of the clinical relevance of chosen 
efficacy and harm outcomes is strongly recommended  
   
Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins 
and washouts), assessments, and visits for participants. A 
schematic diagram is highly recommended  
   
Sample size 14 Estimated number of participants needed to achieve study 
objectives and how it was determined, including clinical and 
statistical assumptions supporting any sample size calculations  
   
Recruitment  15 Strategies for achieving adequate participant enrolment to reach 
target sample size  
   
Methods: Assignment of interventions (for controlled trials)  
Allocation Sequence 
generation 
16a Method of generating the allocation sequence (eg, computer- 
generated random numbers), and list of any factors for 
stratification. To reduce predictability of a random sequence, 
details of any planned restriction (eg, blocking) should be provided 
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in a separate document that is unavailable to those who enrol 
participants or assign interventions  
Allocation 
concealment 
mechanism  
 
16b Mechanism of implementing the allocation sequence (eg, central 
telephone; sequentially numbered, opaque, sealed envelopes), 
describing any steps to conceal the sequence until interventions 
are assigned  
   
Allocation 
implementation 
16c Who will generate the allocation sequence, who will enrol 
participants, and who will assign participants to interventions  
   
 
 
Blinding (masking) 
17a Who will be blinded after assignment to interventions (eg, trial 
participants, care providers, outcome assessors, data analysts), 
and how  
   
17b If blinded, circumstances under which unblinding is permissible, 
and procedure for revealing a participant’s allocated intervention 
during the trial 
   
Methods: Data collection, management, and analysis  
 
 
 
Data collection 
methods 
18a Plans for assessment and collection of outcome, baseline, and 
other trial data, including any related processes to promote data 
quality (eg, duplicate measurements, training of assessors) and a 
description of study instruments (eg, questionnaires, laboratory 
tests) along with their reliability and validity, if known. Reference to 
where data collection forms can be found, if not in the protocol  
   
18b Plans to promote participant retention and complete follow-up, 
including list of any outcome data to be collected for participants 
who discontinue or deviate from intervention protocols  
   
Data management 19 Plans for data entry, coding, security, and storage, including any 
related processes to promote data quality (eg, double data entry; 
range checks for data values). Reference to where details of data 
management procedures can be found, if not in the protocol  
   
Statistical methods 
 
 
20a Statistical methods for analysing primary and secondary 
outcomes. Reference to where other details of the statistical 
analysis plan can be found, if not in the protocol  
   
20b Methods for any additional analyses (eg, subgroup and adjusted 
analyses)  
   
20c Definition of analysis population relating to protocol non-adherence 
(eg, as randomised analysis), and any statistical methods to 
handle missing data (eg, multiple imputation)  
   
Methods: monitoring 
Monitoring 21a Composition of data monitoring committee (DMC); summary of its 
role and reporting structure; statement of whether it is independent 
from the sponsor and competing interests; and reference to where 
further details about its charter can be found, if not in the protocol. 
Alternatively, an explanation of why a DMC is not needed  
 
   
 21b Description of any interim analyses and stopping guidelines, 
including who will have access to these interim results and make 
the final decision to terminate the trial 
   
Harms 22 Plans for collecting, assessing, reporting, and managing solicited 
and spontaneously reported adverse events and other unintended 
effects of trial interventions or trial conduct  
   
 
Auditing 
23 Frequency and procedures for auditing trial conduct, if any, and 
whether the process will be independent from investigators and the 
sponsor  
   
Ethics and dissemination  
Research ethics 
approval 
24 Plans for seeking research ethics committee/institutional review 
board (REC/IRB) approval  
   
Protocol 
amendments 
25 Plans for communicating important protocol modifications (eg, 
changes to eligibility criteria, outcomes, analyses) to relevant 
parties (eg, investigators, REC/IRBs, trial participants, trial 
registries, journals, regulators)  
   
Consent or assent 26a Who will obtain informed consent or assent from potential trial 
participants or authorised surrogates, and how (see Item 32)  
   
26b Additional consent provisions for collection and use of participant 
data and biological specimens in ancillary studies, if applicable  
   
Confidentiality 27 How personal information about potential and enrolled participants 
will be collected, shared, and maintained in order to protect 
confidentiality before, during, and after the trial  
   
Declaration of 
interests 
28 Financial and other competing interests for principal investigators 
for the overall trial and each study site  
   
Access to data 29 Statement of who will have access to the final trial dataset, and 
disclosure of contractual agreements that limit such access for 
investigators  
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Ancillary and post-
trial care 
30 Provisions, if any, for ancillary and post-trial care, and for 
compensation to those who suffer harm from trial participation  
   
Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to 
participants, healthcare professionals, the public, and other 
relevant groups (eg, via publication, reporting in results databases, 
or other data sharing arrangements), including any publication 
restrictions  
   
31b Authorship eligibility guidelines and any intended use of 
professional writers  
   
31c Plans, if any, for granting public access to the full protocol, 
participant- level dataset, and statistical code  
   
Informed consent 
materials 
32 Model consent form and other related documentation given to 
participants and authorised surrogates  
   
Biological 
specimens 
33 Plans for collection, laboratory evaluation, and storage of biological 
specimens for genetic or molecular analysis in the current trial and 
for future use in ancillary studies, if applicable  
   
Additional information 
Year of protocol publication  
Journal name  
Journal SPIRIT endorsement           Yes  = 1          No =0  
 
Study setting           Single site =0                      Multi-center  =1 
Funding source          Non-industry =0                 Industry  =1 
Short description of intervention 
 
       
 
Instructions for data collection.  
1. Read the protocol and capture and rate each checklist item.  
2. After reading a section meant to address a particular aspect of the protocol as defined by the checklist items, 
highlight the section and insert a comment on the PDF document that shows the checklist item it talks about and 
comment on whether the issue is adequately/completely addressed as per the SPIRIT checklist. 
3. Enter the rating on the data extraction worksheet based on the judgement made from the comment in the document. 
4. After rating each item and collecting the additional information on the data extraction form save the PDF document 
with comments with new file name (eg Ref ID 2071 extracted).  
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Appendix E: Excluded protocols  
Study Reason for exclusion 
Skowron 
1990 
outside selected time period  
Thabane 
2011 
duplicate  
Strathdee 
2015 
not RCT 
Naserbakht 
2014 
duplicate  
Oyeledun 
2014 
duplicate  
McCoy 1990 outside selected time period 
Martinez 
2018 
Pilot study 
Lebouche 
2015 
pilot study 
Lebouche 
2014 
Pilot study 
Laisaar 2013 not protocol 
Hirshfield 
2016 
Not HIV treatment, prevention or care intervention or outcomes  
Hargreaves 
2016 
Not HIV treatment, prevention or care intervention or outcomes 
Jongbloed 
2016 
Pilot study 
Jones 2015 duplicate  
James 1995 outside selected time period  
Iwuji 2013 Pilot study  
Inwani 2017 Pilot study 
Garner 2017 Not HIV treatment, prevention or care intervention or outcomes 
Fowler 2014 not protocol 
Fielding 
2015 
Not targeting HIV 
Hanke 2000 not protocol 
Gwadz 2017 not RCT  
Grangeiro 
2015 
not RCT  
Darbes 2014 duplicate  
Cote 2015 Not HIV treatment, prevention or care intervention or outcomes 
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Coovadia 
2012 
not protocol 
Conrad 2014 not protocol  
Cobbing 
2015 
Not HIV treatment, prevention or care intervention or outcomes 
Coates 2014 not protocol  
Callahan 
2007 
Not protocol  
Claborn 
2018 
Pilot study 
Anon 2016 not protocol  
Achillion 
2010 
not RCT 
Achillion 
2008 
not RCT 
Abramsky 
2012 
Not HIV treatment, prevention or care intervention or outcomes 
Aboulker 
1998 
not RCT 
Bigna 2013 Not HIV treatment, prevention or care intervention or outcomes 
Beattie 2016 Not HIV treatment, prevention or care intervention or outcomes 
Beattie 2015 Not HIV treatment, prevention or care intervention or outcomes 
Bozzette 
1990 
Outside selected time period 
Belenko 
2013 
Not HIV treatment, prevention or care intervention or outcomes 
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Appendix F: Included protocols characteristics and their references 
Table of individual protocol characteristics 
Study ID  Year 
publi
shed 
Journal Study 
design 
Setting Geo 
region 
Popula
tion 
Funding Interventio
n category 
Interventi
on target 
Ezeanolue 
2013 2013 
Implementation 
Science CRT Single  Africa Adults 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Testing, 
linkage 
and 
retention 
in care 
Woelk 
2016 2016 Trials CRT Multiple Africa Adults 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Testing, 
linkage 
and 
retention 
in care 
Chang 2017 2017 Trials CRT Multiple Africa Adults 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Testing, 
linkage 
and 
retention 
in care 
Choko 2017 2017 Trials CRT Multiple Africa Adults 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Testing, 
linkage 
and 
retention 
in care 
Nosyk 2015 2015 
Contemporary 
Clinical Trials 
Stepped 
wedge 
CRT Multiple 
N. 
America Adults 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Testing, 
linkage 
and 
retention 
in care 
Aliyu 2013 2013 
Contemporary 
Clinical Trials CRT Multiple Africa 
Adult 
women 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Testing, 
linkage 
and 
retention 
in care 
Tomlinson 
2016 2016 Trials CRT Multiple Africa 
Childre
n 1-
5years 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Testing, 
linkage 
and 
retention 
in care 
Odeny 
2018 2018 Trials CRT Multiple Africa 
Adult 
women 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Adherenc
e and 
retention 
in care 
Wechsberg 
2014 2014 
BMC public 
health CRT Multiple Africa 
Adult 
women 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Risk 
reduction 
and 
Testing 
Gwadz 
2015 2015 
BMC public 
health 
Parallel 
RCT Single  
N. 
America Adults 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Testing, 
linkage 
and 
retention 
in care 
Wamuti 
2015 2015 
Implementation 
Science CRT Multiple Africa Adults 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Testing, 
linkage 
and 
retention 
in care 
Sando 2014 2014 Trials CRT Multiple Africa 
Adult 
women 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Testing, 
linkage 
and 
retention 
in care 
McCrimmo
n 2018 2018 Trials CRT Multiple Asia 
Adult 
women 
Non-
Industy 
HIV 
prevention 
and 
treatment 
Testing 
and viral 
load 
suppressi
on 
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Mustanski 
2017 2017 
JMIR Research 
protocols 
Parallel 
RCT Multiple 
N. 
America MSM 
Non-
Industy 
HIV 
prevention 
Risk 
reduction 
and 
Testing 
Jones 2014 2014 Trials CRT Multiple Africa Adults 
Non-
Industy 
HIV 
prevention 
Testing, 
linkage 
and 
retention 
in care 
Brody 2018 2018 Trials 
Parallel 
RCT Multiple Asia 
Adult 
women 
Non-
Industy 
HIV 
prevention 
Testing, 
linkage 
and 
retention 
in care 
Kuhns 2017 2017 
BMC public 
health 
Parallel 
RCT Multiple 
N. 
America Adults 
Non-
Industy 
HIV 
prevention  
Protected 
sex and 
STI 
preventio
n 
Tomlinson 
2011 2011 Trials CRT Single  Africa 
Adult 
women 
Non-
Industy 
HIV 
prevention 
Testing, 
linkage 
and 
retention 
in care 
Hayes 2014 2014 Trials CRT Multiple Africa Adults 
Non-
Industy 
HIV 
prevention 
Testing, 
linkage 
and 
retention 
in care 
Chambers 
2016 2016 
BMC public 
health 
Parallel 
RCT Single  
N. 
America Adults 
Non-
Industy 
HIV 
prevention 
Risk 
reduction 
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Appendix G: Generalised estimation equations analyses output 
opened on:  19 Nov 2018, 20:44:37 
. do "C:\Users\moleenz\AppData\Local\Temp\STD2fb4_000000.tmp" 
 
1. Univariate analysis for publication period 
The publication period was coded as pre-SPIRIT (2008 to 2013) =0 and post-SPIRIT (2014 t0 
2018) = 1. The GEE model was offset by 1 for inapplicable items. The model was adjusted for 
journal clustering. There was no statistically significant association between publication 
period and number of SPIRIT checklist items reported.  
 
. xtgee spirit_score pubyear2, family(poisson) link(log) 
i(journalclust)offset(lnapplicable_items) corr(exchangeable) vce(robust 
> ) eform 
 
Iteration 1: tolerance = .03254896 
Iteration 2: tolerance = .00393008 
Iteration 3: tolerance = .00020671 
Iteration 4: tolerance = 8.182e-06 
Iteration 5: tolerance = 3.522e-07 
 
GEE population-averaged model                    Number of obs       =         79 
Group variable: journalclust        Number of groups  =        12 
Link:                                  log        Obs per group: 
Family:                             Poisson                       min =          1 
Correlation:                     exchangeable                      avg =         6.6 
                                                                  max =         28 
                                                         Wald chi2(1)      =       2.07 
Scale parameter:                         1             Prob > chi2       =     0.1503 
 
                           (Std. Err. adjusted for clustering on journalclust) 
------------------------------------------------------------------------------ 
                      |               Robust 
spirit_score |        IRR   Std. Err.      z             P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
pubyear2 |   1.051612   .0367945     1.44     0.150     .9819137    1.126258 
       _cons |   .6006125   .0246593   -12.42   0.000     .5541745    .6509417 
lnapplicable_items|          1  (offset) 
------------------------------------------------------------------------------ 
Note: _cons estimates baseline incidence rate (conditional on zero random effects). 
 
2. Univariate analysis for study setting 
The study setting was coded as single site =0 and multi-site=1. The model was adjusted for 
journal clustering. There was no statistically significant association between study setting 
and number of SPIRIT checklist items reported.  
 
. xtgee spirit_score singlevsmultisite , family(poisson) link(log) i( journalclust ) 
offset(lnapplicable_items) corr(exchangeable 
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> ) vce(robust) eform 
 
Iteration 1: tolerance = .02248596 
Iteration 2: tolerance = .00650162 
Iteration 3: tolerance = .00052308 
Iteration 4: tolerance = .00002396 
Iteration 5: tolerance = 1.213e-06 
Iteration 6: tolerance = 6.031e-08 
 
GEE population-averaged model                    Number of obs        =         79 
Group variable:               journalclust       Number of groups  =         12 
Link:                                  log       Obs per group: 
Family:                            Poisson                       min =          1 
Correlation:                  exchangeable                      avg  =        6.6 
                                                                  max =         28 
                                                       Wald chi2(1)      =       0.14 
Scale parameter:                         1             Prob > chi2       =     0.7077 
 
                                (Std. Err. adjusted for clustering on journalclust) 
----------------------------------------------------------------------------------- 
                      |                          Robust 
     spirit_score    |    IRR               Std. Err.              z    P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
singlevsmultisite|   1.023059      .0622046       0.37   0.708     .9081244     1.15254 
                  _cons |      .6111217    .028753     -10.47   0.000     .5572873       .6701566 
lnapplicable_items|          1  (offset) 
----------------------------------------------------------------------------------- 
Note: _cons estimates baseline incidence rate (conditional on zero random effects). 
 
3. Univariate analysis for type of intervention 
Two dummy variables were created since there were three categories: HIV prevention, HIV 
treatment and prevention, HIV care and treatment. HIV prevention was the reference 
category. The treatvsprev2 dummy variable = HIV prevention and treatment.  The model 
was adjusted for journal clustering. There was no statistically significant association 
between type of intervention and number of SPIRIT checklist items reported.  
 
. xtgee spirit_score treatvsprev2 , family(poisson) link(log) i( journalclust ) 
offset(lnapplicable_items) corr(exchangeable) vce 
> (robust) eform 
 
Iteration 1: tolerance = .02490265 
Iteration 2: tolerance = .00509635 
Iteration 3: tolerance = .00035103 
Iteration 4: tolerance = .00001437 
Iteration 5: tolerance = 7.051e-07 
GEE population-averaged model                     Number of obs     =         79 
Group variable:               journalclust        Number of groups  =         12 
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Link:                                  log         Obs per group: 
Family:                            Poisson                        min =          1 
Correlation:                  exchangeable                      avg =        6.6 
                                                                   max =         28 
                                                          Wald chi2(1)      =       0.58 
Scale parameter:                         1               Prob > chi2       =     0.4465 
 
                           (Std. Err. adjusted for clustering on journalclust) 
------------------------------------------------------------------------------ 
              |                Robust 
spirit_score  |        IRR    Std. Err.      z          P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
treatvsprev2  |   1.029212   .0389278     0.76    0.446     .9556744    1.108408 
       _cons  |   .6202574   .0228264   -12.98   0.000     .5770939    .6666493 
lnapplicable_items|          1  (offset) 
------------------------------------------------------------------------------ 
Note: _cons estimates baseline incidence rate (conditional on zero random effects). 
 
4. Univariate analysis for type of intervention 
Two dummy variables were created since there were three categories: HIV prevention, HIV 
treatment and prevention, HIV care and treatment. HIV prevention was the reference 
category. The treatvsprev3 dummy variable = HIV treatment and care.  The model was 
adjusted for journal clustering. There was no statistically significant association between 
type of intervention and number of SPIRIT checklist items reported.  
 
. xtgee spirit_score treatvsprev3 , family(poisson) link(log) i( journalclust ) 
offset(lnapplicable_items) corr(exchangeable) vce 
> (robust) eform 
 
Iteration 1: tolerance = .02069848 
Iteration 2: tolerance = .00530636 
Iteration 3: tolerance = .00039882 
Iteration 4: tolerance = .00001575 
Iteration 5: tolerance = 7.186e-07 
 
GEE population-averaged model                     Number of obs     =         79 
Group variable:               journalclust        Number of groups  =         12 
Link:                                  log         Obs per group: 
Family:                            Poisson                        min =          1 
Correlation:                  exchangeable                       avg =        6.6 
                                                                   max =         28 
                                                          Wald chi2(1)      =       0.00 
Scale parameter:                         1                 Prob > chi2       =     0.9950 
 
                           (Std. Err. adjusted for clustering on journalclust) 
------------------------------------------------------------------------------ 
              |                Robust 
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spirit_score  |        IRR    Std. Err.      z            P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
treatvsprev3  |   1.000172   .0276529      0.01   0.995     .9474153    1.055866 
       _cons  |   .6225471   .0187249   -15.76   0.000     .5869078    .6603506 
lnapplicable_items|          1  (offset) 
------------------------------------------------------------------------------ 
Note: _cons estimates baseline incidence rate (conditional on zero random effects). 
 
5. Multivariate analysis with all factors  
The model was adjusted for journal clustering. There was no statistically significant 
association between type of intervention and number of SPIRIT checklist items reported. 
None of the factors evaluated were significantly associated with number of checklist items 
reported. 
 
. xtgee spirit_score pubyear2 singlevsmultisite treatvsprev2 treatvsprev3, family(poisson) 
link(log) i( journalclust)offset(lnapp 
> licable_items) corr(exchangeable) vce(robust) eform 
 
Iteration 1: tolerance = .01939099 
Iteration 2: tolerance = .00501982 
Iteration 3: tolerance = .00035611 
Iteration 4: tolerance = 7.509e-06 
Iteration 5: tolerance = 1.752e-07 
GEE population-averaged model                     Number of obs     =         79 
Group variable:               journalclust        Number of groups  =         12 
Link:                                  log         Obs per group: 
Family:                            Poisson                        min =          1 
Correlation:                  exchangeable                       avg =        6.6 
                                                                   max =         28 
                                                          Wald chi2(4)      =       8.26 
Scale parameter:                         1               Prob > chi2       =     0.0826 
 
                                (Std. Err. adjusted for clustering on journalclust) 
----------------------------------------------------------------------------------- 
                       |                           Robust 
     spirit_score     |        IRR             Std. Err.          z       P>|z|     [95% Conf. Interval] 
------------------+---------------------------------------------------------------- 
         pubyear2     |   1.045058      .0361428     1.27   0.203     .9765671    1.118353 
singlevsmultisite |   1.012966      .0535807     0.24   0.808     .9132105    1.123619 
     treatvsprev2   |   1.028805      .0522055     0.56   0.576     .9314081    1.136387 
     treatvsprev3   |    1.013578     .0396017     0.35   0.730     .9388574    1.094245 
            _cons        |      .5903524   .0412208    -7.55   0.000     .5148455       .6769331 
lnapplicable_items|          1  (offset) 
----------------------------------------------------------------------------------- 
Note: _cons estimates baseline incidence rate (conditional on zero random effects). 
 closed on:  19 Nov 2018, 20:52:07 
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Appendix I: Contemporary Clinical Trials Journal Instructions to 
authors 
CONTEMPORARY CLINICAL TRIALS 
COMMUNICATIONS  
XXX . . 
• Guide for Authors  
. AUTHOR INFORMATION PACK  
GUIDE FOR AUTHORS  
Your Paper Your Way  
We now differentiate between the requirements for new and revised submissions. You 
may choose to submit your manuscript as a single Word or PDF file to be used in the 
refereeing process. Only when your paper is at the revision stage, will you be requested 
to put your paper in to a 'correct format' for acceptance and provide the items required 
for the publication of your article.  
To find out more, please visit the Preparation section below. INTRODUCTION  
Contemporary Clinical Trials Communications accepts for consideration manuscripts 
containing original material if neither the article nor any part of its essential substance, 
tables, or figures has been or will be published or is currently submitted elsewhere 
before appearing in Contemporary Clinical Trials Communication. This restriction does 
not apply to abstracts or press reports published in connection with scientific meetings.  
For more details on how to write a world class paper, please visit our Pharmacology 
Author Resources page.  
Authors are encouraged to submit video material or animation sequences to 
support and enhance your scientific research. For more information please see the 
paragraph on video data below.  
Types of paper  
Beside Full Length Articles (no word limit), Contemporary Clinical Trials 
Communications invites Short Communications (manuscripts of 1500 or fewer words, 
excepting references, tables and figures), Correspondence (500 or fewer words, 12 or 
fewer references), Opinion Papers (no word limit), and Review Articles (no word 
limit) for possible publication.  
Contact details for submission  
For each submission please make sure to complete and attach the author agreement 
form provided through the system. Credit for authorship requires substantial 
contributions to: (a) conception and design, or analysis and interpretation of data; and 
(b) the drafting of the article or critical revision for important intellectual content.  
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For questions please contact the co-Editors-in-Chief Dr. Zheng Su, E-mail: 
zhengsucctc@gmail.com and Dr. Zhezhen Jin, E-mail: zzjincctc@gmail.com.  
Submission checklist  
You can use this list to carry out a final check of your submission before you send it to 
the journal for review. Please check the relevant section in this Guide for Authors for 
more details.  
Ensure that the following items are present:  
One author has been designated as the corresponding author with contact details: • E-
mail address 
• Full postal address  
All necessary files have been uploaded: 
Manuscript: 
• Include keywords 
• All figures (include relevant captions) 
• All tables (including titles, description, footnotes) 
• Ensure all figure and table citations in the text match the files provided • Indicate 
clearly if color should be used for any figures in print Graphical Abstracts / Highlights 
files (where applicable)  
Supplemental files (where applicable)  
Further considerations 
• Manuscript has been 'spell checked' and 'grammar checked' 
• All references mentioned in the Reference List are cited in the text, and vice versa  
 
AUTHOR INFORMATION PACK 22 Mar 2018 www.elsevier.com/locate/conctc 3  
 
• Permission has been obtained for use of copyrighted material from other sources 
(including the Internet) 
• A competing interests statement is provided, even if the authors have no competing 
interests to declare  
• Journal policies detailed in this guide have been reviewed 
• Referee suggestions and contact details provided, based on journal requirements  
For further information, visit our Support Center. BEFORE YOU BEGIN  
Ethics in publishing  
Please see our information pages on Ethics in publishing and Ethical guidelines for 
journal publication.  
Human and animal rights  
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If the work involves the use of human subjects, the author should ensure that the work 
described has been carried out in accordance with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki) for experiments involving humans; Uniform 
Requirements for manuscripts submitted to Biomedical journals. Authors should include 
a statement in the manuscript that informed consent was obtained for experimentation 
with human subjects. The privacy rights of human subjects must always be observed.  
All animal experiments should comply with the ARRIVE guidelines and should be carried 
out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated 
guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of 
Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, 
revised 1978) and the authors should clearly indicate in the manuscript that such 
guidelines have been followed.  
Conflict of interest  
All of other submitted work that could influence, their work. See Conflict of Interest 
http://www.elsevier.com/__data/promis_misc/AUTHOR%20DECLARATION%20CONCLI_
CONCTC.docx.  
Submission declaration and verification  
Submission of an article implies that the work described has not been published 
previously (except in the form of an abstract, a published lecture or academic thesis, see 
'Multiple, redundant or concurrent publication' for more information), that it is not under 
consideration for publication elsewhere, that its publication is approved by all authors 
and tacitly or explicitly by the responsible authorities where the work was carried out, 
and that, if accepted, it will not be published elsewhere in the same form, in English or in 
any other language, including electronically without the written consent of the copyright- 
holder. To verify originality, your article may be checked by the originality detection 
service Crossref Similarity Check.  
Preprints  
Please note that preprints can be shared anywhere at any time, in line with Elsevier's 
sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior 
publication (see 'Multiple, redundant or concurrent publication' for more information).  
Changes to authorship  
Authors are expected to consider carefully the list and order of authors before 
submitting their manuscript and provide the definitive list of authors at the time of the 
original submission. Any addition, deletion or rearrangement of author names in the 
authorship list should be made only before the manuscript has been accepted and only 
if approved by the journal Editor. To request such a change, the Editor must receive the 
following from the corresponding author: (a) the reason for the change in author list 
and (b) written confirmation (e-mail, letter) from all authors that they agree with the 
addition, removal or rearrangement. In the case of addition or removal of authors, this 
includes confirmation from the author being added or removed.  
authors are requested to disclose any interest including any financial, personal  
actual or potential relationships conflict with the be perceived to also 
https://www.elsevier.com/conflictsofinterest. Our form can be found at: people or 
organizations within three inappropriately influence, or beginning or other years. Only in 
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exceptional circumstances will the Editor consider the addition, deletion or 
rearrangement of authors after the manuscript has been accepted. While the Editor 
considers the request, publication of the manuscript will be suspended. If the manuscript 
has already been published in an online issue, any requests approved by the Editor will 
result in a corrigendum.  
Article transfer service  
This journal is part of our Article Transfer Service. This means that if the Editor feels 
your article is more suitable in one of our other participating journals, then you may be 
asked to consider transferring the article to one of those. If you agree, your article will 
be transferred automatically on your behalf with no need to reformat. Please note that 
your article will be reviewed again by the new journal. More information.  
Copyright  
Upon acceptance of an article, authors will be asked to complete an 'Exclusive License 
Agreement' (see more information on this). Permitted third party reuse of open access 
articles is determined by the author's choice of user license.  
Author rights  
As an author you (or your employer or institution) have certain rights to reuse your 
work. More information.  
Elsevier supports responsible sharing  
Find out how you can share your research published in Elsevier journals.  
Role of the funding source  
You are requested to identify who provided financial support for the conduct of the 
research and/or preparation of the article and to briefly describe the role of the 
sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; 
in the writing of the report; and in the decision to submit the article for publication. If 
the funding source(s) had no such involvement then this should be stated.  
Funding body agreements and policies  
Elsevier has established a number of agreements with funding bodies which allow 
authors to comply with their funder's open access policies. Some funding bodies will 
reimburse the author for the Open Access Publication Fee. Details of existing agreements 
are available online.  
Open access  
This is an open access journal: all articles will be immediately and permanently free for 
everyone to read and download. To provide open access, this journal has an open access 
fee (also known as an article publishing charge APC) which needs to be paid by the 
authors or on their behalf e.g. by their research funder or institution. Permitted third 
party (re)use is defined by the following Creative Commons user licenses:  
Creative Commons Attribution (CC BY)  
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Lets others distribute and copy the article, create extracts, abstracts, and other revised 
versions, adaptations or derivative works of or from an article (such as a translation), 
include in a collective work (such as an anthology), text or data mine the article, even 
for commercial purposes, as long as they credit the author(s), do not represent the 
author as endorsing their adaptation of the article, and do not modify the article in such 
a way as to damage the author's honor or reputation.  
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)  
For non-commercial purposes, lets others distribute and copy the article, and to include 
in a collective work (such as an anthology), as long as they credit the author(s) and 
provided they do not alter or modify the article.  
The open access publication fee for this journal is USD 1950, excluding taxes. Learn 
more about Elsevier's pricing policy: https://www.elsevier.com/openaccesspricing.  
Elsevier Researcher Academy  
Researcher Academy is a free e-learning platform designed to support early and mid-
career researchers throughout their research journey. The "Learn" environment at 
Researcher Academy offers several interactive modules, webinars, downloadable guides 
and resources to guide you through the process of writing for research and going 
through peer review. Feel free to use these free resources to improve your submission 
and navigate the publication process with ease.  
Language (usage and editing services)  
Please write your text in good English (American or British usage is accepted, but not a 
mixture of these). Authors who feel their English language manuscript may require 
editing to eliminate possible grammatical or spelling errors and to conform to correct 
scientific English may wish to use the English Language Editing service available from 
Elsevier's WebShop.  
Informed consent and patient details  
Studies on patients or volunteers require ethics committee approval and informed 
consent, which should be documented in the paper. Appropriate consents, permissions 
and releases must be obtained where an author wishes to include case details or other 
personal information or images of patients and any other individuals in an Elsevier 
publication. Written consents must be retained by the author and copies of the consents 
or evidence that such consents have been obtained must be provided to Elsevier on 
request. For more information, please review the Elsevier Policy on the Use of Images or 
Personal Information of Patients or other Individuals. Unless you have written permission 
from the patient (or, where applicable, the next of kin), the personal details of any 
patient included in any part of the article and in any supplementary materials (including 
all illustrations and videos) must be removed before submission.  
Submission  
Our online submission system guides you stepwise through the process of entering your 
article details and uploading your files. The system converts your article files to a single 
PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required 
to typeset your article for final publication. All correspondence, including notification of 
the Editor's decision and requests for revision, is sent by e-mail.  
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Referees  
Please submit the names and institutional e-mail addresses of several potential referees. 
For more details, visit our Support site. Note that the editor retains the sole right to 
decide whether or not the suggested reviewers are used.  
Submission Categories & Reviewers: When submitting a manuscript to 
Contemporary Clinical Trials Communications, the author will need to assign it to one of 
the following major categories:  
Clinical Trial Results Special Interest Paper Clinical Trial Management Optimization 
Patient Recruitment Patient Registries Study Design, Statistical Methods, Study Protocols  
PREPARATION  
Peer review  
This journal operates a single blind review process. All contributions are typically sent to 
a minimum of two independent expert reviewers to assess the scientific quality of the 
paper. The Editor is responsible for the final decision regarding acceptance or rejection 
of articles. The Editor's decision is final. More information on types of peer review.  
Use of word processing software  
It is important that the file be saved in the native format of the word processor used. 
The text should be in single-column format. Keep the layout of the text as simple as 
possible. Most formatting codes will be removed and replaced on processing the article. 
In particular, do not use the word processor's options to justify text or to hyphenate 
words. However, do use bold face, italics, subscripts, superscripts etc. When preparing 
tables, if you are using a table grid, use only one grid for each individual table and not a 
grid for each row. If no grid is used, use tabs, not spaces, to align columns. The 
electronic text should be prepared in a way very similar to that of conventional 
manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of 
figures, tables and text graphics will be required whether or not you embed your figures 
in the text. See also the section on Electronic artwork.  
To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 
'grammar-check' functions of your word processor.  
Article structure  
Subdivision - numbered sections  
Divide your article into clearly defined and numbered sections. Subsections should be 
numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section 
numbering). Use this numbering also for internal cross-referencing: do not just refer to 
'the text'. Any subsection may be given a brief heading. Each heading should appear on  
Introduction  
State the objectives of the work and provide an adequate background, avoiding a 
detailed literature survey or a summary of the results.  
Material and methods  
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Provide sufficient details to allow the work to be reproduced by an independent 
researcher. Methods that are already published should be summarized, and indicated by 
a reference. If quoting directly from a previously published method, use quotation marks 
and also cite the source. Any modifications to existing methods should also be described.  
Results  
Results should be clear and concise.  
Discussion  
This should explore the significance of the results of the work, not repeat them. A 
combined Results and Discussion section is often appropriate. Avoid extensive citations 
and discussion of published literature.  
Conclusions  
The main conclusions of the study may be presented in a short Conclusions section, 
which may stand alone or form a subsection of a Discussion or Results and Discussion 
section.  
Appendices  
If there is more than one appendix, they should be identified as A, B, etc. Formulae and 
equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; 
in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table 
A.1; Fig. A.1, etc.  
Essential title page information  
• Title. Concise and informative. Titles are often used in information-retrieval systems. 
Avoid abbreviations and formulae where possible. 
• Author names and affiliations. Please clearly indicate the given name(s) and family 
name(s) of each author and check that all names are accurately spelled. You can add 
your name between parentheses in your own script behind the English transliteration. 
Present the authors' affiliation addresses (where the actual work was done) below the 
names. Indicate all affiliations with a lower- case superscript letter immediately after the 
author's name and in front of the appropriate address. Provide the full postal address of 
each affiliation, including the country name and, if available, the e-mail address of each 
author.  
• Corresponding author. Clearly indicate who will handle correspondence at all stages 
of refereeing and publication, also post-publication. This responsibility includes 
answering any future queries about Methodology and Materials. Ensure that the e-mail 
address is given and that contact details are kept up to date by the 
corresponding author.  
• Present/permanent address. If an author has moved since the work described in 
the article was done, or was visiting at the time, a 'Present address' (or 'Permanent 
address') may be indicated as a footnote to that author's name. The address at which 
the author actually did the work must be retained as the main, affiliation address. 
Superscript Arabic numerals are used for such footnotes.  
Abstract  
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A concise and factual abstract is required. The abstract should state briefly the purpose 
of the research, the principal results and major conclusions. An abstract is often 
presented separately from the article, so it must be able to stand alone. For this reason, 
References should be avoided, but if essential, then cite the author(s) and year(s). Also, 
non-standard or uncommon abbreviations should be avoided, but if essential they must 
be defined at their first mention in the abstract itself.  
Keywords  
Immediately after the abstract, provide a maximum of 6 keywords, using American 
spelling and avoiding general and plural terms and multiple concepts (avoid, for 
example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established 
in the field may be eligible. These keywords will be used for indexing purposes.  
Abbreviations  
Define abbreviations that are not standard in this field in a footnote to be placed on the 
first page of the article. Such abbreviations that are unavoidable in the abstract must be 
defined at their first mention there, as well as in the footnote. Ensure consistency of 
abbreviations throughout the article.  
Acknowledgements  
Collate acknowledgements in a separate section at the end of the article before the 
references and do not, therefore, include them on the title page, as a footnote to the 
title or otherwise. List here those individuals who provided help during the research 
(e.g., providing language help, writing assistance or proof reading the article, etc.).  
Formatting of funding sources  
List funding sources in this standard way to facilitate compliance to funder's 
requirements:  
Funding: This work was supported by the National Institutes of Health [grant numbers 
xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and 
the United States Institutes of Peace [grant number aaaa].  
It is not necessary to include detailed descriptions on the program or type of grants and 
awards. When funding is from a block grant or other resources available to a university, 
college, or other research institution, submit the name of the institute or organization 
that provided the funding.  
If no funding has been provided for the research, please include the following sentence:  
This research did not receive any specific grant from funding agencies in the public, 
commercial, or not-for-profit sectors.  
Footnotes  
Footnotes should be used sparingly. Number them consecutively throughout the article. 
Many word processors can build footnotes into the text, and this feature may be used. 
Otherwise, please indicate the position of footnotes in the text and list the footnotes 
themselves separately at the end of the article. Do not include footnotes in the 
Reference list.  
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Artwork  
Electronic artwork 
General points 
• Make sure you use uniform lettering and sizing of your original artwork. 
• Embed the used fonts if the application provides that option. 
• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, 
Symbol, or use fonts that look similar. 
• Number the illustrations according to their sequence in the text. 
• Use a logical naming convention for your artwork files. 
• Provide captions to illustrations separately. 
• Size the illustrations close to the desired dimensions of the published version. 
• Submit each illustration as a separate file. 
A detailed guide on electronic artwork is available. 
You are urged to visit this site; some excerpts from the detailed information are 
given here. Formats 
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, 
Excel) then please supply 'as is' in the native document format. 
Regardless of the application used other than Microsoft Office, when your electronic 
artwork is finalized, please 'Save as' or convert the images to one of the following 
formats (note the resolution requirements for line drawings, halftones, and line/halftone 
combinations given below): 
EPS (or PDF): Vector drawings, embed all used fonts. 
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 
dpi. 
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum 
of 1000 dpi. TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), 
keep to a minimum of 500 dpi. 
Please do not: 
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these 
typically have a low number of pixels and limited set of colors; 
• Supply files that are too low in resolution; 
• Submit graphics that are disproportionately large for the content.  
Color artwork  
Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or 
PDF), or MS Office files) and with the correct resolution. If, together with your accepted 
article, you submit usable color figures then Elsevier will ensure, at no additional charge, 
that these figures will appear in color online (e.g., ScienceDirect and other sites) 
regardless of whether or not these illustrations are reproduced in color in the printed 
version. For color reproduction in print, you will receive information regarding 
the costs from Elsevier after receipt of your accepted article. Please indicate your 
preference for color: in print or online only. Further information on the preparation of 
electronic artwork.  
Illustration services  
Elsevier's WebShop offers Illustration Services to authors preparing to submit a 
manuscript but concerned about the quality of the images accompanying their article. 
Elsevier's expert illustrators can produce scientific, technical and medical-style images, 
as well as a full range of charts, tables and graphs. Image 'polishing' is also available, 
where our illustrators take your image(s) and improve them to a professional standard. 
Please visit the website to find out more.  
Figure captions  
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Ensure that each illustration has a caption. Supply captions separately, not attached to 
the figure. A caption should comprise a brief title (not on the figure itself) and a 
description of the illustration. Keep text in the illustrations themselves to a minimum but 
explain all symbols and abbreviations used.  
Tables  
Please submit tables as editable text and not as images. Tables can be placed either 
next to the relevant text in the article, or on separate page(s) at the end. Number tables 
consecutively in accordance with their appearance in the text and place any table notes 
below the table body. Be sparing in the use of tables and ensure that the data presented 
in them do not duplicate results described elsewhere in the article. Please avoid using 
vertical rules and shading in table cells.  
References  
Citation in text  
Please ensure that every reference cited in the text is also present in the reference list 
(and vice versa). Any references cited in the abstract must be given in full. Unpublished 
results and personal communications are not recommended in the reference list, but 
may be mentioned in the text. If these references are included in the reference list they 
should follow the standard reference style of the journal and should include a 
substitution of the publication date with either 'Unpublished results' or 'Personal 
communication'. Citation of a reference as 'in press' implies that the item has been 
accepted for publication.  
Reference links  
Increased discoverability of research and high quality peer review are ensured by online 
links to the sources cited. In order to allow us to create links to abstracting and indexing 
services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the 
references are correct. Please note that incorrect surnames, journal/book titles, 
publication year and pagination may prevent link creation. When copying references, 
please be careful as they may already contain errors. Use of the DOI is encouraged.  
A DOI can be used to cite and link to electronic articles where an article is in-press and 
full citation details are not yet known, but the article is available online. A DOI is 
guaranteed never to change, so you can use it as a permanent link to any electronic 
article. An example of a citation using DOI for an article not yet in an issue is: VanDecar 
J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of 
the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical 
Research, https://doi.org/10.1029/2001JB000884. Please note the format of such 
citations should be in the same style as all other references in the paper.  
Web references  
As a minimum, the full URL should be given and the date when the reference was last 
accessed. Any further information, if known (DOI, author names, dates, reference to a 
source publication, etc.), should also be given. Web references can be listed separately 
(e.g., after the reference list) under a different heading if desired, or can be included in 
the reference list.  
Data references  
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This journal encourages you to cite underlying or relevant datasets in your manuscript 
by citing them in your text and including a data reference in your Reference List. Data 
references should include the following elements: author name(s), dataset title, data 
repository, version (where available), year, and global persistent identifier. Add 
[dataset] immediately before the reference so we can properly identify it as a data 
reference. The [dataset] identifier will not appear in your published article.  
References in a special issue  
Please ensure that the words 'this issue' are added to any references in the list (and any 
citations in the text) to other articles in the same Special Issue.  
Reference management software  
Most Elsevier journals have their reference template available in many of the most 
popular reference management software products. These include all products that 
support Citation Style Language styles, such as Mendeley and Zotero, as well as 
EndNote. Using the word processor plug-ins from these products, authors only need to 
select the appropriate journal template when preparing their article, after which citations 
and bibliographies will be automatically formatted in the journal's style. If no template is 
yet available for this journal, please follow the format of the sample references and 
citations as shown in this Guide.  
Reference style 
Text: Indicate references by number(s) in square brackets in line with the text. The 
actual authors can be referred to, but the reference number(s) must always be given. 
Example: '..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result 
....' 
List: Number the references (numbers in square brackets) in the list in the order in 
which they appear in the text. 
Examples: 
Reference to a journal publication: 
[1] J. van der Geer, J.A.J. Hanraads, R.A. Lupton, The art of writing a scientific article, J. 
Sci. Commun. 163 (2010) 51–59. 
Reference to a book: 
[2] W. Strunk Jr., E.B. White, The Elements of Style, fourth ed., Longman, New York, 
2000. Reference to a chapter in an edited book: 
[3] G.R. Mettam, L.B. Adams, How to prepare an electronic version of your article, in: 
B.S. Jones, R.Z. Smith (Eds.), Introduction to the Electronic Age, E-Publishing Inc., New 
York, 2009, pp. 281–304. Reference to a website: 
[4] Cancer Research UK, Cancer statistics reports for the UK. 
http://www.cancerresearchuk.org/ aboutcancer/statistics/cancerstatsreport/, 2003 
(accessed 13 March 2003). 
Reference to a dataset: 
[dataset] [5] M. Oguro, S. Imahiro, S. Saito, T. Nakashizuka, Mortality data for Japanese 
oak wilt disease and surrounding forest compositions, Mendeley Data, v1, 2015. 
https://doi.org/10.17632/ xwj98nb39r.1.  
Journal abbreviations source  
Journal names should be abbreviated according to the List of Title Word Abbreviations.  
Video  
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Elsevier accepts video material and animation sequences to support and enhance your 
scientific research. Authors who have video or animation files that they wish to submit 
with their article are strongly encouraged to include links to these within the body of the 
article. This can be done in the same way as a figure or table by referring to the video or 
animation content and noting in the body text where it should be placed. All submitted 
files should be properly labeled so that they directly relate to the video file's content. . In 
order to ensure that your video or animation material is directly usable, please provide 
the file in one of our recommended file formats with a preferred maximum size of 150 
MB per file, 1 GB in total. Video and animation files supplied will be published online in 
the electronic version of your article in Elsevier Web products, including ScienceDirect. 
Please supply 'stills' with your files: you can choose any frame from the video or 
animation or make a separate image. These will be used instead of standard icons and 
will personalize the link to your video data. For more detailed instructions please visit 
our video instruction pages. Note: since video and animation cannot be embedded in the 
print version of the journal, please provide text for both the electronic and the print 
version for the portions of the article that refer to this content.  
Supplementary material  
Supplementary material such as applications, images and sound clips, can be published 
with your article to enhance it. Submitted supplementary items are published exactly as 
they are received (Excel or PowerPoint files will appear as such online). Please submit 
your material together with the article and supply a concise, descriptive caption for each 
supplementary file. If you wish to make changes to supplementary material during any 
stage of the process, please make sure to provide an updated file. Do not annotate any 
corrections on a previous version. Please switch off the 'Track Changes' option in 
Microsoft Office files as these will appear in the published version.  
Research data  
This journal encourages and enables you to share data that supports your research 
publication where appropriate, and enables you to interlink the data with your published 
articles. Research data refers to the results of observations or experimentation that 
validate research findings. To facilitate reproducibility and data reuse, this journal also 
encourages you to share your software, code, models, algorithms, protocols, methods 
and other useful materials related to the project.  
Below are a number of ways in which you can associate data with your article or make a 
statement about the availability of your data when submitting your manuscript. If you 
are sharing data in one of these ways, you are encouraged to cite the data in your 
manuscript and reference list. Please refer to the "References" section for more 
information about data citation. For more information on depositing, sharing and using 
research data and other relevant research materials, visit the research data page.  
Data linking  
If you have made your research data available in a data repository, you can link your 
article directly to the dataset. Elsevier collaborates with a number of repositories to link 
articles on ScienceDirect with relevant repositories, giving readers access to underlying 
data that gives them a better understanding of the research described.  
There are different ways to link your datasets to your article. When available, you can 
directly link your dataset to your article by providing the relevant information in the 
submission system. For more information, visit the database linking page.  
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For supported data repositories a repository banner will automatically appear next to 
your published article on ScienceDirect.  
In addition, you can link to relevant data or entities through identifiers within the text of 
your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; 
CCDC: 734053; PDB: 1XFN).  
Mendeley Data  
This journal supports Mendeley Data, enabling you to deposit any research data 
(including raw and processed data, video, code, software, algorithms, protocols, and 
methods) associated with your manuscript in a free-to-use, open access repository. 
During the submission process, after uploading your manuscript, you will have the 
opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will 
be listed and directly accessible to readers next to your published article online.  
For more information, visit the Mendeley Data for journals page.  
Data statement  
To foster transparency, we encourage you to state the availability of your data in your 
submission. This may be a requirement of your funding body or institution. If your data 
is unavailable to access or unsuitable to post, you will have the opportunity to indicate 
why during the submission process, for example by stating that the research data is 
confidential. The statement will appear with your published article on ScienceDirect. For 
more information, visit the Data Statement page.  
Drug Names. Generic names should generally be used. When proprietary brands are 
used in research, include the brand name in parentheses to refer to drugs.  
Permissions. Materials taken from other sources must be accompanied by a written 
statement from both author and publisher giving permission to Contemporary Clinical 
Trials Communications for reproduction. For unpublished data and personal 
communications, obtain permission in writing from at least one author.  
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Review. The editorial staff reviews all manuscripts. Two outside referees review all 
manuscripts accepted for peer review. The editorial staff encourages authors to suggest 
names of possible reviewers, but reserves the right of final selection.  
AFTER ACCEPTANCE  
Online proof correction  
Corresponding authors will receive an e-mail with a link to our online proofing system, 
allowing annotation and correction of proofs online. The environment is similar to MS 
Word: in addition to editing text, you can also comment on figures/tables and answer 
questions from the Copy Editor. Web-based proofing provides a faster and less error-
prone process by allowing you to directly type your corrections, eliminating the potential 
introduction of errors.  
If preferred, you can still choose to annotate and upload your edits on the PDF version. 
All instructions for proofing will be given in the e-mail we send to authors, including 
alternative methods to the online version and PDF. 
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We will do everything possible to get your article published quickly and accurately. 
Please use this proof only for checking the typesetting, editing, completeness and 
correctness of the text, tables and figures. Significant changes to the article as accepted 
for publication will only be considered at this stage with permission from the Editor. It is 
important to ensure that all corrections are sent back to us in one communication. 
Please check carefully before replying, as inclusion of any subsequent corrections cannot 
be guaranteed. Proofreading is solely your responsibility.  
Offprints  
The corresponding author will be notified and receive a link to the published version of 
the open access article on ScienceDirect. This link is in the form of an article DOI link 
which can be shared via email and social networks. For an extra charge, paper offprints 
can be ordered via the offprint order form which is sent once the article is accepted for 
publication. Both corresponding and co-authors may order offprints at any time via 
Elsevier's Webshop. Authors requiring printed copies of multiple articles may use Elsevier 
Webshop's 'Create Your Own Book' service to collate multiple articles within a single 
cover.  
AUTHOR INQUIRIES  
Visit the Elsevier Support Center to find the answers you need. Here you will find 
everything from Frequently Asked Questions to ways to get in touch. 
You can also check the status of your submitted article or find out when your accepted 
article will be published.  
© Copyright 2018 Elsevier | https://www.elsevier.com  
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